Progress in HIV therapeutics and the challenges of adherence to antiretroviral therapy

Infectious Disease Clinics of North America

Volumn 14, Issue 4, 2000, Pages 901-928

  Andrews, Laurie ^b   Friedland, Gerald ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ARTICLE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAINTENANCE THERAPY; PATIENT ATTITUDE; PATIENT CARE; PATIENT COMPLIANCE; PATIENT MONITORING;

EID: 0034494004     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5520(05)70139-2     Document Type: Article

References (109)

1. The era of adherence of HIV therapy
2. Perceptions, acceptance and adherence, to antiretrovirals among prisoners
3. Dropping out of treatment: A critical review
4. Spontaneous adherence audits predict viral suppression in the REACH cohort
5. Adherence to ART associated with seminal viral level (SVL) suppression
6. Prospective monitoring of indinavir or saquinavir level in hair samples from 132 HIV-infected patients and correlation with response to highly active antiretroviral therapy and selection of resistant mutants
7. HIV drug resistance in newly infected individuals
8. Detection methods and strategies for improving medication compliance
9. The care of HIV-infected adults in the United States
10. Low adherence in antiretroviral users at Sao Paulo, Brazil
11. A cohort study of drug users' compliance with zidovudine treatment
12. Obstacles in treatment adherence: Patient reasons
13. Antiretroviral therapy for HIV infection in 1998: Updated recommendations of the International AIDS Society-USA Panel
14. Compliance to multiple combination therapy with antiprotease inhibitors among HIV-infected IDUs in France (Cohort MANIF 2000)
15. Patient-doctor communication
16. Antiretroviral use and adherence predicted by active illicit drug use
17. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy
18. Zidovudine pharmacokinetics in HIV-positive women during different phases of the menstrual cycle
19. How often is medication taken as prescribed? A novel assessment technique
20. AIDS in Blackface
21. Variations in patients' compliance with doctor's advice: An empirical analysis of patterns of communication
22. Successful ritonavir induction: Intensive patient management
23. Viral load and CD4 T cell changes in patients, failing potent protease inhibitor therapy
24. Self-reported adherence to HAART and correlation with HIV RNA: Initial results with the Patient Medication Adherence Questionnaire
25. Compliance with antihypertensive regimen: A review of the research in the 1980's
26. Serum protease inhibitor level as a marker of adherence HAART: Correlation with self-reported adherence and with HIV RNA
27. Understanding and improving patient compliance
28. Changing AIDS-risk behavior
29. Drug compliance in patients starting saquinavir
30. Alliance not compliance: A philosophy of outpatient care
31. Compliance with AZT treatment regimen of HIV-positive injection drug users: A neglected issue
32. Attaining higher goals in HIV treatment: The central importance of adherence
33. Adherence to antiretroviral regimens in HIV-infected patients: Results of a survey among physicians and patients
34. Self-reported adherence to combination antiretroviral medication (ARV) regimens in a community-based sample of HIV-infected adults
35. Adherence to anti-retroviral therapy: A four country comparison
36. Self-reported adherence to protease inhibitors substantially overestimates an objective measure
37. Physician perceptions of HIV (1) IDCs as barriers to treatment
38. A review of the factors associated with patient compliance and the taking of prescribed medicines
39. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
40. High viral load in semen of human immunodeficiency virus type 1-infected men at all stages of disease and its reduction by therapy with protease and nonnucleoside reverse transcriptase inhibitors
41. Once daily therapy (NVP/dd1/3TC) for the IVDU HIV-1 infected population of the Frankfurt HIV cohort
42. Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy
43. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response
44. Viral dynamics of HIV: Implications for drug development and therapeutic strategies
45. Determinants of compliance: The disease and the mechanics of treatment
46. A critical review of the "determinants" of patient compliance with therapeutic regimens
47. Systematic review of randomised trials of interventions to assist patients to follow prescriptions for medications
48. Adherence and effectiveness of protease inhibitors in clinical practice
49. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors
50. Patients' beliefs about HAART influence adherence to antiretroviral therapy
51. Medication use and misuse: Physician-patient discrepancies
52. Adherence and retention in AIDS clinical trials: A framework for research and application
53. Adherence to highly active antiretroviral therapy among HIV-infected patients of the inner city
54. Adherence to combination antiretroviral therapies in HIV patients of low health literacy
55. Characterizing patterns of drug-taking behavior with a multiple drug regimen in an AIDS clinical trial
56. Predictors of non-adherence to HIV combination therapies
57. Strategies to optimise adherence to highly active antiretroviral treatment
58. Effect of antiretroviral therapy on vaginal HIV RNA level
59. A test of the construct validity of health locus of control: Effects on self-reported compliance for hypertensive patients
60. Reduced antiretroviral drug susceptibility among patients with primary HIV infection
61. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions
62. The effect of instruction and labeling on the number of medication errors made by patients at home
63. The impact of the ALR™ alarm device on antiretroviral (AR) adherence among HIV-infected outpatients in Harlem
64. Methods of improving patient compliance
65. Factors affecting adherence
66. Providers' estimates of adherence overestimate reports from medication event monitoring system (MEMS) for patients on protease inhibitors (PIs)
67. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The INCAS Trial. Italy, The Netherlands, Canada, and Australia Study
68. Effectiveness of combination antiretroviral therapy in clinical practice
69. Concurrent and predictive validity of self-reported measure of medication adherence
70. Determinants of subject compliance within an experimental anti HIV drug protocol
71. Acceptance and adherence with antiretroviral therapy among HIV-infected women in a correctional facility
72. Zidovudine adherence among individuals with HIV infection
73. Preparing for side effects
74. Relationship of self-reported adherence to HAART with protease inhibitor (PI) plasma level and viral load (VL)
75. Medical care for injection drug users with human immunodeficiency virus infection
76. Adherence to antiretroviral therapy (ART) among women in the HIV Epidemiology Research Study (HERS) and Women's Inter-Agency HIV Study
77. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
78. How much adherence is enough? A prospective study of adherence to protease inhibitor therapy using MEMS caps
79. The limited value of therapeutic drug monitoring in HIV infection
80. Locus of control and adjustment to chronic haemodialysis
81. Drug defaulting in general practice
82. Stages and processes of self-change of smoking: Toward an integrative model of change
83. Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study
84. Historical origins of the health belief model
85. Effectiveness of interventions to improve patient compliance: A meta analysis
86. The magnitude of compliance and noncompliance
87. Compliance with zidovudine therapy in patients infected with human immunodeficiency virus, type A: A cross-sectional study in a municipal hospital clinic
88. HIV therapy in the real world
89. The impact of patient-reported adherence with antiretroviral therapy on virologic response
90. Determinants of compliance with antiretroviral therapy in patients with human immunodeficieney virus: Prospective assessment with implications for enhancing compliance
91. The relationship between literacy, race and adherence to potent anti-retroviral theraphies
92. Methods of assessing and improving compliance in clinical trials
93. A pilot program of modified directly observed therapy (MDOT) to enhance adherence to highly active antiretroviral therapy (HAART): 6-month follow-up
94. Physician-patient communication and patient conformity with medical advice
95. A phase III, multicenter, randomized, open-label study to compare the antiretroviral activity and tolerability of efaviren (EFV) + indinavir (IDV), versus EFV zidovudine (ZDV) + lamivudine (3TC), versus IDV + ZDV + 3TC at 48 weeks (study 266-006)
96. A specific intervention improves long term adherence to HAART and ensuing virologic outcome
97. Errors in prescribing HIV-1 protease inhibitors
98. Patient compliance and drug failure in protease inhibitor monotheraphy
99. Public health implications of antiretroviral therapy and HIV drug resistance
100. Adherence to zidovudine (AZT) among methadone maintenance patients: On-site dispensing compared to usual care
101. Adherence to proteinase inhibitor based highly effective antiretroviral therapy (HEART)
102. The effect of directly observed therapy on the rates on drug resistance and relapse in tuberculosis
103. Patient characteristics and attitudes associated with antiretroviral adherence
104. Hypertension: A community problem
105. Impact of interventions on adherence rates